News

DecisionView Announces Availability of Software-As-A-Service Offering

New model delivers lower cost of ownership, faster implementation time, and lower entry point

SAN FRANCISCO – September 30, 2009 – DecisionView, Inc., the leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the immediate availability of the Software-as-a-Service (SaaS) version of StudyOptimizer, the company’s flagship solution. Under the new model, DecisionView will provide hosting, implementation, and support of StudyOptimizer on a pay-as-you-go basis that is available for individual trials.

"It is not uncommon for life sciences companies to experience enrollment delays in one or more critical studies. In cases like these, the need for an application like StudyOptimizer becomes significant" said Jim Scullion, CEO of DecisionView. "We realized the importance of accelerating the adoption of our solution, so that customers could implement corrective actions in their enrollment processes as quickly as possible. With the launch of this new offering, companies can leverage the planning and forecasting capabilities of StudyOptimizer in a shorter timeframe, even on a single trial."

Hosted in a SAS70 certified infrastructure that provides robust security and privacy features, the new model is designed to deliver a lower cost of ownership and rapid deployment of StudyOptimizer on any number of studies, providing study managers, recruitment planners, and other personnel managing the enrollment process with a fast way to access DecisionView’s world-class enrollment planning capabilities.

Designed for organizations conducting clinical trials, StudyOptimizer is a global collaborative solution which fosters best practices and automates the clinical enrollment process by integrating a robust forecasting model, rich visualizations, and enrollment planning capabilities resulting in shorter cycle times, reduced recruitment costs and improved clinical operational efficiencies.

DecisionView Board of Directors Appoints James P. Scullion as CEO and President

High Tech Industry Veteran Will Focus on Broader Product Distribution, Revenue Growth and Profitability

SAN FRANCISCO – March 30, 2009 – DecisionView, Inc., the leading provider of Clinical Optimization Solutions for the Life Sciences industry, today announced that its Board of Directors has appointed James P. Scullion to the role of Chairman, President and CEO of DecisionView, effective immediately. Most recently, he held the role of Chairman for DecisionView. Scullion succeeds Steve Andrade as the Company’s President and Chief Executive Officer.

"I'm very pleased that Jim has agreed to join DecisionView as its new CEO," said Chris Hollenbeck, a DecisionView Board Member. "We believe the market for clinical optimization solutions is poised for significant growth. Jim has over two decades of experience leading high tech companies, and his expertise will greatly benefit DecisionView as the company looks to extend its leadership position as a comprehensive provider of business performance optimization applications."

Mr. Scullion brings more than 20 years of experience as a “C” level executive in the high technology industry to his new position. Most recently, he served as Chairman and CEO of Tumbleweed Communications from January 2006 to September 2008. Under Mr. Scullion’s leadership, Tumbleweed was successfully transformed from an email security centric company to a leading provider of secure content delivery solutions to Global 1000 and midmarket enterprises doubling its customer base from 1,700 to 3,500 customers. Tumbleweed was acquired by Sopra Group in September 2008. From January 2004 to January 2006, he was CEO of ComnetiX, Inc., a leading provider of criminal intelligence systems. During Mr. Scullion’s tenure at Comnetix, revenues grew threefold and he led the company’s successful IPO on the Toronto Stock Exchange. From 1990 to 2002, he held senior management positions including President and COO with Identix Incorporated, a publicly traded biometric technology company. While at Identix, Scullion led the company’s growth in annual revenues from $1 million to more than $80 million.

"DecisionView is the technology leader in the clinical recruitment optimization market," said Scullion. "I am excited to be joining a company that is well positioned to capitalize on a fast growing, high demand market. I believe my leadership and operational experience will further strengthen the already outstanding DecisionView team, and will help accelerate our company’s growth as we expand and enrich our optimization solutions for the Life Sciences industry."

Steve Andrade will be leaving the company to pursue other interests and will also be stepping down from his position as a member of the DecisionView board of directors.

DecisionView Announces Series D Round Investment

Leading Provider of Business Performance Optimization Applications in Life Sciences Secures Capital for Continued Growth

SAN FRANCISCO – December 10, 2008 – DecisionView, Inc., the leading provider of business performance optimization applications for the Life Sciences industry, today announced the close of its Series D investment with Granite Ventures, Adobe Ventures and Aeris Capital.

"The continued confidence demonstrated by our venture capital partners - Granite Ventures, Adobe Ventures and Aeris Capital, further validates DecisionView’s business strategy and growth opportunity,” said Steve Andrade, CEO of DecisionView. “Their investment in DecisionView, especially during this dynamic global economic period, allows us to continue to remain acutely focused on our business strategy and deliver innovative solutions and value to the life sciences industry.”

The additional funding will be applied to DecisionView’s strategic growth opportunities for expanding its distinctive platform for improving the performance of clinical trials. This includes the Company’s flagship application, StudyOptimizer, the first Web-based clinical trial enrollment software that enables companies to optimize the clinical trial recruitment and enrollment process for greater predictability, faster cycle times and reduced costs.

“DecisionView’s software continues to make a positive and significant impact on the way life sciences companies approach their clinical studies,” said Chris Hollenbeck, managing director, Granite Ventures. “With the increased economic and operational pressures on pharmaceutical companies today, DecisionView is poised for significant growth with product offerings that provide tangible value.”

“DecisionView is bringing truly unique applications to the clinical trial market and this financing will allow the company to continue to expand on their innovative offerings,” said David Hartford, managing director at Aeris Capital."

Recently, DecisionView announced several new features and enhancements to StudyOptimizer 4.0 including an innovative user interface framework, new analytic engine, an enterprise-class J2EE server and enhanced administration capabilities. Under development for more than a year, StudyOptimizer 4.0 represented a major milestone for DecisionView with new features designed to improve user experience, performance, scalability and reliability.

DecisionView Launches Hosted Applications Services for StudyOptimizer

DV OnDemand Reduces Cost of Ownership and Optimizes Clinical Trial Performance

SAN FRANCISCO – December 3, 2008 – DecisionView, Inc., the leading provider of software solutions to optimize clinical trial performance for life sciences companies, today announced the availability of DV OnDemand, a suite of application hosting and managed services for StudyOptimizer, the company’s flagship solution that optimizes the clinical trial recruitment and enrollment process. Developed in direct response to market demand from leading pharmaceutical and biotech companies, the DV OnDemand solution lowers the cost of supporting on-going operations as a critical element to overall clinical trial success.

"Pharmaceutical and biotech companies worldwide are challenged to cost effectively support the increasingly complex demands of their internal departments and clinical operations users,” said Steve Andrade, CEO, DecisionView. “We realized the growing need to offer multiple options in providing a seamless and convenient experience for our customers and their IT departments. DV OnDemand ensures that the software runs on a highly scalable, secure and available infrastructure effectively relieving the challenges associated with maintaining software applications on-premise.”

DecisionView has partnered with OpSource for its strategic hosting solution needs in order to ensure that its customers’ stringent security and availability requirements were met. OpSource, known for its extensive experience supporting mission-critical business applications, provides secure, comprehensive services with an impressive performance based track record and innovative on-demand platform.

"In today's economy, companies must find secure, efficient ways to achieve their goals; this is particularly true for companies in the clinical trials field where millions of dollars are spent before a single dollar is earned," said OpSource CEO Treb Ryan. "DecisionView decided to meet its clients' needs by providing a seamless on-demand solution that offered a high degree of security and met all audit requirements, and realized that to do so would require partnering with an experienced, award-winning on-demand solutions provider. We are proud that DecisionView recognizes our experience in this field as well as our commitment to providing our partners with a high quality on-demand product.”

DecisionView’s hosted deployment includes separate servers for development, training, testing and production. Development and testing systems allow clients to review new features before upgrading their production systems, while dedicated training systems support initial rollout activities and ongoing training initiatives. In order to maintain the highest level of data security, the environments are completely isolated from other clients and SAS70 certified. The configurations include Apache application servers running on MS Windows Enterprise and Oracle 10g running on Redhat ES V5, and day-to-day operations are managed by a team of Systems Engineers and Network Administrators, guaranteeing optimized performance, up-time, and security.

DecisionView plans to further leverage OpSource’s expertise with virtualization and SaaS capabilities to continue to stay ahead of the market in adopting new technologies to simplify operations and reduce cost of ownership for its customers.

DecisionView Named “Best Market Solution” by IDC

Leading Software Solutions Provider Awarded at the Life Sciences Technology Insight Conference

SAN FRANCISCO – October 7, 2008 – DecisionView, Inc., the leading provider of software solutions to optimize clinical trial performance for life sciences companies, received the “Best Market Solution” award at the IDC Technology Insight conference held in Philadelphia on September 14-16, 2008.

With approximately 60,000 clinical trials taking place annually, stringent FDA requirements, and drug manufacturers competing amongst themselves for patients, sometimes thousands of patients need to be recruited globally to get approval for just a single drug. The increase in complexity has made it difficult for most life sciences companies to manage the process with ordinary tools.

“We set our vision for a fully integrated application that automates the critical clinical trial recruitment process and integrates real time visibility and predictability for improving cycle time performance and cost efficiencies,” said Steve Andrade, CEO of DecisionView. “This award validates StudyOptimizer as an innovative technology approach for improving this critical and complex clinical trial process. We are honored that IDC executive participants recognized our company’s solution and commitment to helping solve the clinical trial recruitment issue.”

IDC Life Sciences Technology Insight 2008 conference was held in Philadelphia on September 14-16, 2008, and the audience included pharmaceutical IT executives, solution providers and thought leaders. Additionally, major pharmaceutical organizations, such as Pfizer, Merck, Wyeth, Bristol-Myers Squibb, Johnson & Johnson, were also in attendance. Focused on the new generation of technologies for the life sciences, the event is produced by PPM Media with IDC’s Health Industry Insights as content partner.

The awards are determined by the attending executives who vote upon the best vendor presentations and solutions showcased at the summit. DecisionView won the “Best Market Solution” via the direct vote. Other nominees in this category included Adobe, IBM and Medidata.

“PPM Media congratulates DecisionView on its award at our recent Life Sciences Technology Insight summit,” said Philip McKay, President and CEO of PPM Media. “Because winners and nominees are directly determined by pharmaceutical IT executives from across North America, DecisionView’s “Best Market Solution” award for their revolutionary StudyOptimizer is further recognition of their technology leadership and ongoing innovation in the life sciences marketplace.”

DecisionView Executive, Dr. Cosimo Spera, to speak at upcoming DIA Conference

Session focuses on Future Advancements in Models and Algorithms for the Optimization of Clinical Trial Recruitment: Using Science to Deliver Superior Business Results

SAN FRANCISCO – May 29, 2008 – DecisionView Inc., the leading provider of software solutions designed to improve time to market and reduce clinical trial costs for life sciences companies, confirmed that Dr. Cosimo Spera will be delivering a session at the Drug Information Association annual event from 10:30am - 12:00pm June 25, 2008.

For more than 20 years, academic researchers and practitioners have studied patient recruitment in clinical trials. While a variety of models and algorithms have been presented and discussed at a theoretical level, real world implementations have lacked success mostly because of the complexity of the proposed models and algorithms and the difficulty in gathering the data required at the right time. Dr. Cosimo Spera, DecisionView, Dr. Valerii V Fedorov, and Dr. Vladimir V. Anisimov, both with GlaxoSmithKline Pharmaceuticals will cover how to overcome these challenges.

DecisionView Appoints Life Sciences Software Expert, Gonzalo Castro, to Vice President of Product Marketing

The Leading Provider of Business Performance Optimization Applications in Life Sciences Strengthens Product Management Team

SAN FRANCISCO – January 29, 2008 – DecisionView Inc., the leading provider of software solutions designed to improve time to market and reduce clinical trial costs for life sciences companies, today announced the appointment of Gonzalo Castro as Vice President, Product Marketing and a member of the company’s management team.

With over 10 years of industry experience, Mr. Castro is a seasoned product marketing leader who has an impressive track record in developing and commercializing successful and market leading software products for the Life Sciences industry. “We are delighted to welcome Gonzalo to the DecisionView management team,” said Steve Andrade, CEO of DecisionView. “His expertise in the Life Sciences industry, coupled with his software application development and product marketing experience, makes him a strategic addition to our growing company.”

Mr. Castro joins DecisionView from Oracle Corporation, where he was Director of Life Sciences Product Strategy. Prior to Oracle, he worked at Siebel Systems in a number of roles within the Life Sciences Product Marketing group, successfully conceiving, developing, and launching applications that are used by some of the largest global pharmaceutical companies. In addition to his software career, Mr. Castro served as an Operations Research Consultant at ZS Associates where he applied advanced modeling and optimization algorithms to enhance sales and marketing strategies, generating new revenue streams for the company. Mr. Castro holds an MS in Industrial Engineering from Purdue University and an MBA from the Wharton School of Business.

“DecisionView is an exciting software company that is focused on solving significant clinical trial performance challenges using innovative analytical and predictive modeling approaches,” said Gonzalo Castro. “The market is ready for an application solution that improves the speed of clinical trials by optimizing the clinical trial enrollment process. The recent enhancements to StudyOptimizer 3.5.3, released this week, are a proof point to the company’s ongoing commitment to develop innovative solutions that deliver business value to the life sciences industry,” Castro continued.

DecisionView Appoints Technology Industry Veteran, Rene Pharisien, to Vice President of Worldwide Sales

The Leading Provider of Business Performance Optimization Applications in Life Sciences Strengthens Executive Management Team

SAN FRANCISCO – December 11, 2007 – DecisionView Inc., the leading provider of software solutions designed to improve time to market and reduce clinical trial costs for life sciences companies, today announced the appointment of Rene Pharisien as Vice President of Worldwide Sales and a member of the company’s executive management team.

With over 25 years of sales and marketing experience in the high tech industry, Mr. Pharisien has developed a strong track record for driving significant revenue growth, cultivating strong customer relationships and developing successful strategic business partnerships. “We are pleased to welcome Rene to DecisionView and the executive management team. His experience in building and leading high performance sales organizations in high growth technology companies will be a tremendous asset to the company,” said Steve Andrade, CEO of DecisionView.

Rene began his technology sales career with Prime Computer where he quickly rose through the ranks becoming one of the youngest managers in the company’s history. He subsequently held key posts at several leading technology companies including Siebel Systems, Sequent and 3Com. Most recently Mr. Pharisien was Senior Vice President of Worldwide Sales at Kintera, a “Software-as-a-Service” company and previously held executive management positions with Niku as Vice President of Marketing and at Epiphany where he was Western Area Vice President of Sales.

“I am delighted to join DecisionView and look forward to executing on the company’s compelling vision and strategy. The clinical trial process is mission critical for life sciences companies and managing that process effectively is a key component in reducing costs and improving effectiveness in the healthcare industry,” said Rene Pharisien. “StudyOptimizer^TM is a revolutionary software solution that is at the nexus of solving one of the biggest challenges faced by pharmaceutical and biotechnology companies—bringing new therapies to market faster and more cost effectively,” Pharisien continued.

DecisionView Announces $7 Million in Series C Investment

The Leading Provider of Business Performance Optimization Applications in Life Sciences Secures Funding for Growth

SAN FRANCISCO — July 30, 2007 – DecisionView, Inc., the leading provider of business performance optimization applications for the Life Sciences industry, today announced the close of a $7 million Series C round of funding led by new investor, firstVentury, as well as existing investors Partech International and Granite Ventures.

"We are delighted to be working with firstVentury. Their experience with convergent technologies in Life Sciences and relationships with European companies makes them a logical partner for DecisionView," said Steve Andrade, CEO of DecisionView. "FirstVentury's participation validates our growing leadership in delivering innovative clinical performance optimization solutions that deliver tangible business results."

In addition to the funding, David Hartford, Managing Director, firstVentury, will be joining DecisionView's Board of Directors. "We are delighted to welcome David to our Board. His experience in the IT and Life Sciences technology domains will further complement the strength and contributions of our existing board members," continued Andrade.

"DecisionView epitomizes the convergence of IT and life science which firstVentury sees as an absolute necessity in bringing affordable new treatments to market rapidly," said David Hartford, managing director, firstVentury. "We are very pleased to be part of DecisionView's move to radically improve the clinical trials process."

The funding will be used to scale its commercial growth capabilities and expand DecisionView's suite of clinical performance optimization applications, including the company's innovative clinical recruitment platform, StudyOptimizer^TM. As the industry's first business performance optimization application for clinical trials, StudyOptimizer automates the recruitment process with integrated predictive modeling, simulation, planning, and rich visualization capabilities. The company was also recently named in the list of "Cool Vendors" in the "Cool Vendors in Life Sciences, 2007" report by Gartner, Inc.

"DecisionView has made great strides in developing top-tier solutions to meet the demanding needs of the Life Sciences industry," said Tom McKinley, managing partner and co-founder, Partech International. "The company and its leading-edge technology are well-poised for significant growth."

"DecisionView has developed a terrific solution for life sciences companies, and this financing will allow the company to expand its reach in the market, as well as continue to innovate," said Granite Ventures managing director Chris Hollenbeck.

DecisionView Launches StudyOptimizerTM 3.5 for Improved Clinical Trial Performance

StudyOptimizer 3.5 Enhances Clinical Recruitment Performance & Delivers Measurable Business Results

SAN FRANCISCO – April 30, 2007 – DecisionView Inc., the leading provider of business performance optimization software for the life sciences industry, announced today the immediate availability of StudyOptimizer 3.5 – the industry’s first business performance optimization application for clinical trials.

Designed for pharmaceutical, biotech, CRO, medical technology companies and academic research institutions, StudyOptimizer 3.5 automates the clinical recruitment process with integrated predictive modeling, analytics, simulation and rich visualization capabilities resulting in shorter cycle times, reduced recruitment costs and improved clinical operational efficiencies.

“Delays in recruitment are a leading cause of overall clinical trial delays and escalating clinical trial costs. StudyOptimizer 3.5 provides life science companies with a comprehensive application for improving the mission critical recruitment process and achieving tangible business results,” said Steve Andrade, CEO, DecisionView.

The new version delivers dynamic recruitment planning to include recruitment rate variables such as seasonality for developing robust clinical recruitment plans; advanced simulation modeling and predictive analytics that enable clinical study managers to model course corrections and alternative recruitment strategies; and rich interactive visualizations, including performance alerts and dashboards at the study, country and site level. In addition, StudyOptimizer 3.5 further enhances automated data aggregation from disparate financial and clinical systems such as CTMS and EDC, driving improvements in clinical team productivity.

“Today’s studies must reach a global patient pool and succeed in meeting their enrollment targets. By enabling consistent planning, dynamic performance forecasts and helpful visuals of enrollment progress, DecisionView’s StudyOptimizer can help study management teams succeed in efficient and effective enrollment across multiple countries,” said Jane W. Schafer, Executive Director, Global Study Planning & Technical Services, Amgen Inc.

DecisionView Signs Multi-Year Agreement with GlaxoSmithKline

SAN FRANCISCO – March 19, 2007 – DecisionView Inc., the leading provider of business performance optimization solutions to the life sciences industry, announced today that the company has signed a multi-year agreement with GlaxoSmithKline (GSK) to standardize on DecisionView’s StudyManager application for optimizing clinical recruitment performance. StudyManager is the industry’s first performance optimization solution for clinical trials.

“The number one issue impacting overall clinical trial cost is study delays caused by inadequate recruitment performance; specifically, poor recruitment planning, progress monitoring and execution” said Alex Lancksweert, director of Performance Metrics & Benchmarking in GSK’s Clinical Operations organization. GSK will globally deploy StudyManager across all Phase I-IV studies.

DecisionView’s StudyManager 3.2 application is used by clinical teams to optimize clinical recruitment performance in order to reduce recruitment costs and cycle times by automating planning, progress monitoring, predictive modeling and simulation capabilities within the clinical recruitment process.

“Improved visibility to current and predictive information, and enhanced enterprise agility to execute timely course corrections are critical competitive advantages to pharmaceutical companies and their clinical development performance. We look forward to working with GSK,” said Steve Andrade, CEO, DecisionView.

DecisionView Named Life Sciences "Cool Vendor" by Leading Analyst Firm

Vendors Selected for Gartner’s “Cool Vendor Report” are Innovative, Impactful and Intriguing.

SAN FRANCISCO, March 15, 2007 – DecisionView today announced that the company has been selected as one of the Life Science industry’s “Cool Vendors in Life Sciences, 2007” report by Gartner, Inc.

In the highly competitive life sciences market, where new product development and commercialization are key differentiators, DecisionView's StudyOptimizer application is used by pharmaceutical companies to optimize clinical recruitment performance. Through its unique approach of converging predictive modeling, simulation, visualization and dynamic planning capabilities in an automated clinical business process, StudyOptimizer enables life sciences companies to realize tangible business outcomes. “We are delighted and honored by Gartner’s designation as a Cool Vendor. We believe recognition in the Cool Vendors Report is strong validation of the business value that can be achieved by life sciences companies who adopt DecisionView’s business performance optimization solution,” said Steve Andrade, CEO, DecisionView.

About Gartner's Cool Vendors Selection Process
Gartner's listing does not constitute an exhaustive list of vendors in any given technology area, but rather is designed to highlight interesting, new and innovative vendors, products and services. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness of a particular purpose.

Gartner defines a cool vendor as a company that offers technologies or solutions that are: Innovative, enable users to do things they couldn't do before; Impactful, have, or will have, business impact (not just technology for the sake of technology); Intriguing, have caught Gartner's interest or curiosity in approximately the past six months.

Related Terms:
clinical studies, company info, employment

Quick Links:
View Demo
Request a free ROI analysis
White Papers
Download datasheets
Case Study
Request a Live Demo
Contact Us
Resources

NEWS

News

Featured Articles

News

DecisionView Announces Availability of Software-As-A-Service Offering

DecisionView Board of Directors Appoints James P. Scullion as CEO and President

DecisionView Announces Series D Round Investment

DecisionView Launches Hosted Applications Services for StudyOptimizer

DecisionView Named “Best Market Solution” by IDC

DecisionView Executive, Dr. Cosimo Spera, to speak at upcoming DIA Conference

DecisionView Appoints Life Sciences Software Expert, Gonzalo Castro, to Vice President of Product Marketing

DecisionView Appoints Technology Industry Veteran, Rene Pharisien, to Vice President of Worldwide Sales

DecisionView Announces $7 Million in Series C Investment

DecisionView Launches StudyOptimizerTM 3.5 for Improved Clinical Trial Performance

DecisionView Signs Multi-Year Agreement with GlaxoSmithKline

DecisionView Named Life Sciences "Cool Vendor" by Leading Analyst Firm